WORLD Chinese COVID-19 vaccine to enter late-stage trial in Uzbekistan


Chinese COVID-19 vaccine to enter late-stage trial in Uzbekistan


17:52, November 15, 2020

The Uzbek government has recently told media that the country will carry out a phase-three trial of a China-developed vaccine for COVID-19, which makes the vaccine China's fifth candidate to enter late-stage human tests overseas.

File photo: CGTN

"The third phase of the pilot process will be conducted in Uzbekistan for 5,000 volunteers, and the process will continue for a year," the Ministry of Innovative Development said, adding that the volunteers were aged between 18 and 59 and would undergo eight medical examinations within a year.

The trial vaccine was developed by China's Anhui Zhifei Longcom Biopharmaceutical. Several Chinese specialists will also be dispatched to Uzbekistan to monitor the participants and train Uzbek doctors.

In addition to Zhifei Longcom's product, Uzbekistan is working on testing two more vaccines made by China's Sinopharm and Russia's Sputnik V.

Uzbekistan has so far confirmed 69,987 COVID-19 cases and 594 deaths, with 67,241 patients recovered. About 200 confirmed cases are found every day in November, down from around 250 in October.

The country of 34 million has undergone a national lockdown twice, but a third lockdown is unlikely as President Shavkat Mirziyoyev has told officials to "learn to live and work in pandemic conditions."

The Uzbek government has set up an anti-COVID-19 fund of a billion U.S. dollars. A large part of the fund was used to build infrastructure, buy equipment and train medical staff.

Sources: Xinhua News Agency ,Reuters

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue